StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Tuesday. The brokerage set a “hold” rating on the stock.

Oncternal Therapeutics Stock Performance

Shares of Oncternal Therapeutics stock opened at $0.53 on Tuesday. The firm has a market cap of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The firm’s 50-day simple moving average is $0.73 and its 200-day simple moving average is $2.77. Oncternal Therapeutics has a twelve month low of $0.53 and a twelve month high of $13.14.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.